MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)*
Finance & Acquisitions: Recursion
Exscientia Plc (NASDAQ: EXAI)
Finance & Acquisitions: Exscientia
Parents
Exscientia Plc (NASDAQ: EXAI)
Children
2020: Exscientia raises $60m in Series C round
2021: BlackRock powers Exscientia to $100M series C round to fund autonomous drug design
2021: Exscientia scores $50M upfront from Bristol Myers—and up to $1.2B total—in AI drug discovery deal
2021: Gates Foundation awards $35 million PRI for anti-viral therapeutics
2021: Novo Holdings led the initial series C with support from Evotec, Bristol Myers Squibb and GT Healthcare Capital. The addition of BlackRock to the syndicate has now further swelled the series C
2021: Series D_SoftBank leads funding that could net up to $525M for Exscientia's AI drug platform
2022: Exscientia plc 2022 Q3 - Results - Earnings Call Presentation_ seekingalpha.com
2024: Biotech firm Recursion to buy smaller peer Exscientia for $688 million
2024: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
2024: Recursion, Exscientia Merge to Create AI-Enabled Biotech
2024: Recursion's Acquisition Of Exscientia Makes Sense On Some Levels, Not Others
Jumps
*Key People: Exscientia
Organization & Developments: Exscientia